Figure 4. Phase I pharmacokinetic (PK) results of KDS2010 (IMAGE)
Caption
The pharmacokinetic properties of KDS2010 were evaluated in a Phase I clinical trial in healthy adults. In the single-dose study (a), plasma concentrations increased proportionally with escalating doses ranging from 30 mg to 960 mg, followed by a gradual decline with a consistent half-life. In the multiple-dose study (b), stepwise dose escalation from 60 mg to 480 mg demonstrated stable and predictable PK profiles. Even at higher doses, drug concentrations remained within the safe range. These results indicate that KDS2010 exhibits dose-proportional pharmacokinetics and a favorable safety profile, supporting its potential progression to Phase II clinical trials in spinal cord injury patients.
Credit
Institute for Basic Science
Usage Restrictions
Attribution Required
License
Original content